Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2428416 | 0.84 | LMNA (0.39) | LMNAPKMNPSR1ALDH1A1MAPT | |
| SCHEMBL8939958 | 0.83 | LMNA (0.39) | LMNAPKMNPSR1ALDH1A1MAPT | |
| SCHEMBL2993353 | 0.81 | ALDH1A1 (0.46) | LMNAPKMNPSR1ALDH1A1MAPT | |
| SCHEMBL2432528 | 0.81 | FFAR4 (0.49) | LMNAPKMAKR1C4AKR1C3AKR1C2 | |
| SCHEMBL14292128 | 0.81 | LMNA (0.39) | LMNAPKMNPSR1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL7626508 | 0.80 | FFAR4 (0.48) | LMNAPKMAKR1C4AKR1C3AKR1C2 | |
| SCHEMBL8940032 | 0.79 | SMN1; SMN2 (0.38) | LMNAPKMNPSR1ALDH1A1MAPT | |
| SCHEMBL14683708 | 0.78 | LMNA (0.41) | LMNAPKMNPSR1ALDH1A1MAPT | |
| SCHEMBL4754019 | 0.77 | ALOX15 (0.37) | LMNAPKMNPSR1ALDH1A1MAPT | |
| SCHEMBL30079686 | 0.77 | ALOX15 (0.37) | LMNAPKMNPSR1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| EP-2064192-B1 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY INC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8598374-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130131063-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131063-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20080114167-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY DISCOVERY, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-5563148-A | BICYCLIC ESTERS OR AMIDES; USED IN TREATING MIGRAINE, EMESIS, GASTROINTESTINAL DISORDERS, SCHIZOPHRENIA OR ANXIETY IN MAMMALS | ELI LILLY AND COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0307172-B1 | Improvements in or relating to specific 5-HT3 antagonists | LILLY CO ELI (US) | 1995-10-11 | — | — | EP | disclosed |
| US-5442078-A | Intermediates for specific 5-HT3 antagonists | ELI LILLY AND COMPANY (US) | 1995-08-15 | — | — | US | disclosed |
| US-5364863-A | Treatment of migraine, emesis, schizophrenia, anxiety, gastrointestinal disorders | ELI LILLY AND COMPANY (US) | 1994-11-15 | — | — | US | disclosed |
| CN-1020102-C | Process for producing bicyclic carboxylic acid ester and bicyclic carboxamide | EIL LILLY & CO (US) | 1993-03-17 | — | — | CN | disclosed |
| US-4997956-A | Analgesics | ELI LILLY AND COMPANY (US) | 1991-03-05 | — | — | US | disclosed |
| US-4921982-A | 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids useful as intermediates for 5-HT3 antagonists | ELI LILLY AND COMPANY (US) | 1990-05-01 | — | — | US | disclosed |
| CN-1031841-A | The improvement of special 5-HT3 antagonist | LILLY CO ELI (US) | 1989-03-22 | — | — | CN | disclosed |
| EP-0307172-A2 | Improvements in or relating to specific 5-HT3 antagonists | ELI LILLY AND COMPANY (US) | 1989-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | LMNA 4018/4885PKM 2307/4885AKR1C4 1122/4885 |
| US-20080114167-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | BCL2, BCL2L1, BCL2L11 | LMNA 3721/4885PKM 4310/4885AKR1C4 3862/4885 |
| US-20130131063-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | BCL2, BCL2L1, BCL2L11 | LMNA 3721/4885PKM 4310/4885AKR1C4 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.